



## Clinical trial results: Pharmacokinetics of Proton Pump Inhibitors in a random Icelandic Population.

### Summary

EudraCT number	2015-002230-41
Trial protocol	IS
Global end of trial date	31 March 2017

### Results information

Result version number	v1 (current)
This version publication date	20 November 2021
First version publication date	20 November 2021
Summary attachment (see zip file)	Pharmacokinetics of single and repeated oral doses of esomeprazole and gastrin elevation in healthy males and females (Article.Summary.Report.pdf)

### Trial information

#### Trial identification

Sponsor protocol code	PPH-LYF02
-----------------------	-----------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Landspítali – the National University Hospital of Iceland.
Sponsor organisation address	Hringbraut , Reykjavik , Iceland, 101
Public contact	Einar Stefan Bjornsson, Landspítali University Hospital , landspitali@landspitali.is
Scientific contact	Einar Stefan Bjornsson, Landspítali University Hospital , 354 8253747, einarsb@landspitali.is

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	30 November 2020
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	31 March 2017
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of this work is to identify the pharmacokinetics of proton pump inhibitors (PPI) after a single oral dose and after continuous intake for five days in healthy volunteers.

Protection of trial subjects:

In this study no new medicines will be investigated, only authorized medicinal products on the European market. The study focuses on the question: is there a gender specific difference in the pharmacokinetic of PPIs? The PPI drugs have a very good safety profile and in this study 30 participants, equally many males and females will only receive single dose each morning for five days, so safety should not be issue beyond the usual PPI therapy.

In the Icelandic Health care system, in this case Landspítali, all patients are insured by Icelandic law. Landspítali as a part of the Icelandic socialized and governmental owned and organized health care system, carries its own central insurance plan, backed up by the ministries of Welfare and Finance. The volunteers participating in this study according to appropriately approved protocol, will be assured the same insurance coverage as all other patients receiving treatment at the hospital.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	14 September 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Iceland: 30
Worldwide total number of subjects	30
EEA total number of subjects	30

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	30
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Healthy volunteers were recruited by advertisements in the University Hospital of Iceland and the University of Iceland via email.

### Pre-assignment

Screening details:

Only adults (aged 20 – 50 years) without a history of gastrointestinal (GI) symptoms or use of acid suppressive therapy were invited to participate.

Individuals with known obesity (BMI>30kg/m<sup>2</sup>), chronic infectious diseases such as hepatitis, pregnant or taking known CYP inhibitors or inducers were excluded from the study

### Period 1

Period 1 title	Day 1 (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

Arm title	Study arm
-----------	-----------

Arm description:

This study was a non-blind 1-way trial consisting of 5-day study period.

Arm type	Experimental
Investigational medicinal product name	Esomeprazol
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

The participants received a single oral dose of 40 mg tablet of esomeprazole for five days

Number of subjects in period 1	Study arm
Started	30
Completed	30

## Baseline characteristics

### Reporting groups

Reporting group title	Day 1
-----------------------	-------

Reporting group description: -

Reporting group values	Day 1	Total	
Number of subjects	30	30	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	30	30	
From 65-84 years	0	0	
85 years and over	0	0	
Gender categorical			
Units: Subjects			
Female	15	15	
Male	15	15	

### Subject analysis sets

Subject analysis set title	Day 5
----------------------------	-------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

Subject analysis set description:

Healthy volunteers were recruited by advertisements in the University Hospital of Iceland and the University of Iceland via email. Only adults (aged 20–50 years) without a history of gastrointestinal (GI) symptoms or use of acid suppressive therapy were invited to participate.

Reporting group values	Day 5		
Number of subjects	30		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	30		
From 65-84 years	0		
85 years and over	0		

Gender categorical			
Units: Subjects			
Female	15		
Male	15		

---

## End points

### End points reporting groups

Reporting group title	Study arm
Reporting group description: This study was a non-blind 1-way trial consisting of 5-day study period.	
Subject analysis set title	Day 5
Subject analysis set type	Sub-group analysis
Subject analysis set description: Healthy volunteers were recruited by advertisements in the University Hospital of Iceland and the University of Iceland via email. Only adults (aged 20–50 years) without a history of gastrointestinal (GI) symptoms or use of acid suppressive therapy were invited to participate.	

### Primary: Pharmacokinetic parameters

End point title	Pharmacokinetic parameters
End point description:	
End point type	Primary
End point timeframe: The pharmacokinetic parameters (primary and secondary endpoints) were estimated using noncompartmental analysis on the serum esomeprazole concentration wit	

End point values	Study arm	Day 5		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	30	30		
Units: ng/ml				
number (not applicable)	30	30		

### Statistical analyses

<b>Statistical analysis title</b>	Pharmacokinetic parameters
Comparison groups	Study arm v Day 5
Number of subjects included in analysis	60
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.05
Method	Wilcoxon (Mann-Whitney)
Parameter estimate	Mean difference (final values)
Point estimate	1000
Confidence interval	
level	95 %
sides	1-sided
lower limit	0



## Adverse events

---

### Adverse events information<sup>[1]</sup>

---

Timeframe for reporting adverse events:

During the drug intervention period

---

Adverse event reporting additional description:

During the drug intervention period, researchers will be in telephone contact with participants to follow them up and participants are also given a telephone number to contact on their own initiative. Any unexpected serious adverse effects that may occur follow the drug intake will be notified to the Icelandic Medicines Agency.

---

Assessment type	Non-systematic
-----------------	----------------

---

### Dictionary used

---

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23
--------------------	----

---

Frequency threshold for reporting non-serious adverse events: 5 %

---

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: There were no reports of non-serious adverse events recorded, most likely do to short proton pump inhibitor therapy of only 5 days

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported